Hypertrans®

PBL Technology (PBL) and Leaf Expression Systems Ltd (Leaf) are delighted to announce a further development in their relationship, with PBL granting Leaf the exclusive rights to sub-license the Hypertrans^® transient expression system, the core technology underpinning Leaf’s biologics and vaccines contract development and manufacturing services business.  Apart from rights previously granted to PBL’s pre-existing licensees, this effectively transfers to Leaf full control of the Hypertrans^® technology and associated patented intellectual property.  This extension of Leaf’s rights will ensure that Leaf’s clients are able to use Hypertrans^® for the manufacture of their products in multiple geographical locations, to meet the needs of individual markets and to enable clients to take advantage of lower manufacturing costs in some of these markets.

Please click here for the full press release.

For more information, please email info@pbltechnology.com.